TRIANNI and LakePharma Announce Strategic Technology Partnering Agreement

San Francisco and Belmont, CA, USA, {May 9, 2016} – Trianni, Inc., (TRIANNI)  a private biotech company developing novel antibody discovery platforms, and LakePharma, Inc., the leading CRO offering integrated solutions for biologics discovery and development, today announced a technology partnership to empower antibody drug development. The agreement grants LakePharma the right to utilize the Trianni Mouse Platform for antibody discovery services. Financial terms were not disclosed. LakePharma will be responsible for marketing the Trianni Platform as part of its service offerings in the US.

The Trianni Mouse Platform enables the expression of antibodies with fully human variable domains leveraging in-vivo selection to increase antibody diversity and quality.

“TRIANNI is excited to enter this alliance with LakePharma,” stated Matthias Wabl, Ph.D., Chairman and CEO of TRIANNI. “We believe that the Trianni Platform, coupled with LakePharma’s robust antibody discovery and development service capabilities, will be an invaluable asset to clients seeking to develop antibody therapeutics.”

“Bringing the Trianni Transgenic Mouse Platform in-house allows us to combine a world class, novel technology with LakePharma’s unique immunization platform and screening strategies.  We enable our clients with an unprecedented ability to conduct in vivo discovery of human monoclonal therapeutics in a proven combination of quality platforms,” added Hua Tu, Ph.D., Chairman and CEO of LakePharma.


About Trianni, Inc.
Trianni is a privately held organization, formed in 2010 with a mission to use recent advances in DNA synthesis and genomic modification technology for the development of an optimized therapeutic antibody discovery platform, The Trianni Mouse. The company has research and administrative facilities in the San Francisco Bay Area (CA, USA) and in Research Triangle Park (NC, USA). For more information, please visit

About LakePharma
LakePharma is a contract research organization (CRO) dedicated to serving the discovery research and development needs of companies engaged in the preclinical development of biotherapeutics. The company has assembled the United States’ most comprehensive set of technologies and expertise to offer a large continuum of services for antibody and protein discovery and engineering, cell line creation, and protein analytics. Clients may access our services individually or as a fully integrated “soup to nuts” solution for all of their molecular biology, protein chemistry, cell line, assay, and scale-up needs. For more information, please visit


Contacts- TRIANNI
Mandy Boyd
Director of Marketing
1.415.231.0256 [o]

 Contacts- LakePharma
Norm Garceau Ph.D.
VP of Technology